Application of sodium phenylbutyrate in preparation of medicine for preventing or treating Parkinson's disease

Abstract

The invention relates to the field of biological pharmacy, in particular to application of sodium phenylbutyrate (SP) in preparation of a medicine for preventing or treating Parkinson's disease. The gene co-expression network is explored by integrating multiple omics data, and the medicine SP capable of obviously reversing abnormally expressed genes in the module is obtained. Animal experiments show that the medicine can improve animal behaviors and prevent the development of Parkinson's disease. Therefore, the SP has the effect of preventing the development of the Parkinson's disease and the effect of improving the treatment of the Parkinson's disease.

Description

technical field

[0001] The invention relates to the field of biopharmaceuticals, in particular to the application of sodium phenylbutyrate in the preparation of medicaments for preventing or treating Parkinson's disease. Background technique

[0002] Parkinson's disease (PD) is the second most common neurodegenerative disorder in the world, and there are currently no effective therapies to prevent PD or halt its progression. No matter drug treatment or surgical treatment for this disease at present, can only improve its symptom, can not stop the development of disease, more can't be cured.

[0003] Sodium phenylbutyrate (SP) is generally used in all newborns with enzyme deficiency (complete enzyme deficiency within 28 days after birth), delayed enzyme deficiency with family history of hyperammonemic encephalopathy (after the first month of life) patients with partial enzyme deficiency). Contents of the invention

[0004] The purpose of the present invention is to overcom...

Examples

Embodiment 1

[0021] Example 1 Determination of Primary Cell Synapse Morphology

[0022] Purchasing 0-day C57 suckling mice to extract cortical neuron cells, after the neuron cells grow synapses, give SP treatment for 2 hours, then add ROT to build PD cell models, observe the morphology of cell synapses after 24 hours, apply tubulin to the synapse microtubules The protein was developed, the neuron cells were developed with Neu N, and the number of cells in each 4× field of view was observed with BX86.

[0023] NC: control group;

[0024] ROT: ROT treatment group, given ROT 400μM;

[0025] ROT+SP: ROT group given SP intervention, given SP 1 μM.

[0026] The result is as figure 1 As shown, the number of surviving cells per visual field in the ROT group was 132.67 less than that in the NC group, p=0.012; the number of surviving cells in each visual field in the ROT+SP group was 46.00 more than that in the ROT group, p=0.005.

Embodiment 2

[0027] Embodiment 2 animal experiments and results

[0028] 2.1 Experimental materials and equipment

[0029] 2.1.1 Experimental objects

[0030] The Parkinson's (PD) mouse model, C57BL / 6J mice, was provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (animal license number: SCXK (Beijing) 2016-0011).

[0031] 2.1.2 Experimental conditions

[0032] Clean grade animal room with a temperature of 22-25°C, a relative humidity of 40% to 60%, a 12 / 12h light and dark cycle, and free access to food and water. During the experiment, the animals were raised and collected in accordance with the relevant regulations on the management and protection of experimental animals.

[0033] 2.1.3 Main experimental equipment

[0034] Roche Modular-ISE9OO-P800 automatic biochemical analyzer; electronic balance BP12lS; LDZ5-2 desktop low-speed automatic balance centrifuge; Spectrumlab22PC spectrophotometer; Nippon Kohden MEK-6318K automatic blood cell analyzer; LEICARM2135 ...

technical field

[0001] The invention relates to the field of biopharmaceuticals, in particular to the application of sodium phenylbutyrate in the preparation of medicaments for preventing or treating Parkinson's disease. Background technique

[0002] Parkinson's disease (PD) is the second most common neurodegenerative disorder in the world, and there are currently no effective therapies to prevent PD or halt its progression. No matter drug treatment or surgical treatment for this disease at present, can only improve its symptom, can not stop the development of disease, more can't be cured.

[0003] Sodium phenylbutyrate (SP) is generally used in all newborns with enzyme deficiency (complete enzyme deficiency within 28 days after birth), delayed enzyme deficiency with family history of hyperammonemic encephalopathy (after the first month of life) patients with partial enzyme deficiency). Contents of the invention

[0004] The purpose of the present invention is to overcom...

Examples

Embodiment 1

[0021] Example 1 Determination of Primary Cell Synapse Morphology

[0022] Purchasing 0-day C57 suckling mice to extract cortical neuron cells, after the neuron cells grow synapses, give SP treatment for 2 hours, then add ROT to build PD cell models, observe the morphology of cell synapses after 24 hours, apply tubulin to the synapse microtubules The protein was developed, the neuron cells were developed with Neu N, and the number of cells in each 4× field of view was observed with BX86.

[0023] NC: control group;

[0024] ROT: ROT treatment group, given ROT 400μM;

[0025] ROT+SP: ROT group given SP intervention, given SP 1 μM.

[0026] The result is as figure 1 As shown, the number of surviving cells per visual field in the ROT group was 132.67 less than that in the NC group, p=0.012; the number of surviving cells in each visual field in the ROT+SP group was 46.00 more than that in the ROT group, p=0.005.

Embodiment 2

[0027] Embodiment 2 animal experiments and results

[0028] 2.1 Experimental materials and equipment

[0029] 2.1.1 Experimental objects

[0030] The Parkinson's (PD) mouse model, C57BL / 6J mice, was provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (animal license number: SCXK (Beijing) 2016-0011).

[0031] 2.1.2 Experimental conditions

[0032] Clean grade animal room with a temperature of 22-25°C, a relative humidity of 40% to 60%, a 12 / 12h light and dark cycle, and free access to food and water. During the experiment, the animals were raised and collected in accordance with the relevant regulations on the management and protection of experimental animals.

[0033] 2.1.3 Main experimental equipment

[0034] Roche Modular-ISE9OO-P800 automatic biochemical analyzer; electronic balance BP12lS; LDZ5-2 desktop low-speed automatic balance centrifuge; Spectrumlab22PC spectrophotometer; Nippon Kohden MEK-6318K automatic blood cell analyzer; LEICARM2135 ...

Images